3,517 Shares in Insulet Corporation $PODD Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,517 shares of the medical instruments supplier’s stock, valued at approximately $535,000.

Other institutional investors have also bought and sold shares of the company. Larson Financial Group LLC increased its holdings in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Insulet during the 4th quarter valued at about $26,000. Elyxium Wealth LLC bought a new position in shares of Insulet in the 4th quarter valued at about $28,000. DV Equities LLC bought a new position in shares of Insulet in the 4th quarter valued at about $28,000. Finally, MV Capital Management Inc. purchased a new position in Insulet in the fourth quarter worth about $29,000.

Analysts Set New Price Targets

Several equities research analysts have weighed in on PODD shares. Raymond James Financial reissued an “outperform” rating and set a $180.00 price objective on shares of Insulet in a research note on Thursday, August 6th. BTIG Research lowered Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Benchmark dropped their target price on Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Wells Fargo & Company downgraded Insulet from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $255.00 to $144.00 in a research report on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Insulet in a report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price target on the stock. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Insulet has a consensus rating of “Hold” and a consensus target price of $195.40.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $148.14 on Thursday. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a market capitalization of $10.27 billion, a price-to-earnings ratio of 27.69, a PEG ratio of 1.17 and a beta of 1.08. The firm’s 50-day moving average is $154.73 and its 200 day moving average is $178.59.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.